Epigenetic agents in combined anticancer therapy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10376758" target="_blank" >RIV/00216208:11110/18:10376758 - isvavai.cz</a>
Alternative codes found
RIV/60461373:22340/18:43915999
Result on the web
<a href="https://doi.org/10.4155/fmc-2017-0203" target="_blank" >https://doi.org/10.4155/fmc-2017-0203</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4155/fmc-2017-0203" target="_blank" >10.4155/fmc-2017-0203</a>
Alternative languages
Result language
angličtina
Original language name
Epigenetic agents in combined anticancer therapy
Original language description
In the last decade, epigenetic drugs (such as inhibitors of DNA methyltransferases and histone deacetylases) have been intensively used for cancer treatment. Their applications have shown high anticancer effectivity and tolerable side effects. However, they are unfortunately not effective in the treatment of some types and phenotypes of cancers. Nevertheless, several studies have demonstrated that problems of drug efficacy can be overcome through the combined application of therapeutic modulates. Therefore, combined applications of epigenetic agents with chemotherapy, radiation therapy, immunotherapy, oncolytic virotherapy and hyperthermia have been presented. This review summarizes and discusses the general principles of this approach, as introduced and supported by numerous examples. In addition, predictions of the future potential applications of this methodology are included.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Future Medicinal Chemistry
ISSN
1756-8919
e-ISSN
—
Volume of the periodical
10
Issue of the periodical within the volume
9
Country of publishing house
GB - UNITED KINGDOM
Number of pages
18
Pages from-to
1113-1130
UT code for WoS article
000431874300010
EID of the result in the Scopus database
2-s2.0-85046870876